支气管疾病患儿接受特异性免疫治疗对其免疫指标及促炎因子的影响观察

Observation on the Effect of Specific Immunotherapy on the Immune and Pro-inflammatory Factors in Children with Bronchial Asthma

目的探讨支气管患儿接受特异性免疫治疗(SIT)对其免疫指标及促炎因子的影响。方法选取庆阳市人民医院收治的103例小儿支气管疾病患儿,按随机对照实验(RCT)进行分组实验,其中A组在对症支持治疗的基础上加用SIT治疗,B组单纯予以对症支持治疗,采用SPSS 21.0软件打包处理两组各项临床指标和比较两组患儿各项免疫指标及促炎因子的变换情况及临床症状改善效果。结果 (1)A、B组干预前的IgE、CD3^+、CD4^+、CD8^+、CD4^+/CD8^+等免疫指标无显著差异(P>0.05),且两组治疗后优于治疗前(P<0.05),但A组治疗后的以上指标均显著优于B组(P<0.05)。(2)A组治疗前的IL-4、IL-8、TNF-α、IFN-γ与B组相比无显著差异(P>0.05),治疗后显著优于治疗前,但A组治疗后以上指标均显著优于B组,差异显著(P<0.05)。(3)A、B组治疗前的日间、夜间症状评分无显著差异(P>0.05),治疗后两组均优于治疗前,且A组显著优于B组(P<0.05)。结论在小儿支气管疾病的临床治疗中予以SIT治疗对提升患儿免疫功能、抑制炎症水平以及改善其临床症状均有良好的临床应用价值,效果较好。

OBJECTIVE To study the effect of specific immunotherapy(SIT)on the immune and pro-inflammatory factors in children with bronchial diseases. METHODS 103 children with bronchial diseases were randomly divided into two groups according to RCT. Group A was treated with SIT on the basis of symptomatic support treatment,and group B was treated with symptomatic support alone. SPSS 21.0 Software was used to package the clinical indexes of the two groups and to compare the transformation of immune indexes and pro-inflammatory factors and the improvement of clinical symptoms between the two groups RESULTS(1)there was no significant difference in IgE,CD3^+,CD4^+,CD8^+,CD4^+/CD8^+and other immune indexes between group B and group B before intervention,and the two groups were better than those before treatment(P<0.05). However,the above indexes in group A were significantly better than those in group B after treatment(P<0.05).(2)There was no significant difference in IL-4,IL-8,TNF-αand IFN-γ between group A and group B before treatment(P<0.05). After treatment,the above indexes in group A were significantly better than group B(P<0.05),but the above indexes in group A were significantly better than group B after treatment(P<0.05).(3)There was no significant difference in nocturnal symptom scores between group A and group B before treatment(P>0.05). After treatment,the scores of symptoms in group B were better than those before treatment,and group A was significantly better than group B(P<0.05). CONCLUSION SIT treatment in the clinical treatment of bronchial diseases in children had a good clinical application value to improve the immune function,inhibit the level of inflammation and improve its clinical symptoms,which had great effect.